Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis

The purpose of this study is to evaluate the efficacy and safety of Lifei Qingchang Granules in the treatment of patients with stable bronchiectasis. This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Researchers plan to enroll a total of 150 adult participants (aged 18-75) who have been diagnosed with stable bronchiectasis and experience at least one acute exacerbation in the past 12 months. Participants will be randomly assigned into two groups in a 1:1 ratio: * The treatment group will receive Lifei Qingchang Granules along with standard postural drainage therapy. * The control group will receive a matching placebo along with standard postural drainage therapy. The treatment period will last for 3 months. The main goal is to see if the treatment can improve patients' respiratory symptoms and overall quality of life.

NCT Number	NCT07523165
Lead Sponsor	The First Affiliated Hospital of Guangzhou Medical University Collaborators: Second Affiliated Hospital of Guangzhou Medical University, The Third Affiliated Hospital of Guangzhou Medical University
Conditions	Bronchiectasis
Enrollment	150 participants
Start Date	2026-04
Primary Completion	2028-03 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-13